Biogen, founded in 1978, is a biotechnology company focused on delivering new medicines to improve patient lives. They leverage human biology to develop innovative treatments with superior outcomes. For more information, investors can visit their website or follow them on social media. The company recently released a news statement containing forward-looking statements about their drug development and commercialization efforts, including potential benefits, safety, and regulatory discussions. They caution investors about the risks and uncertainties involved in drug development and urge not to rely solely on these statements. For more information on risks and uncertainties, investors can refer to Biogen’s reports filed with the SEC.

Read more at GlobeNewswire: Biologics License Application for Subcutaneous Formulation